International Isotopes wins Imagyn deal
Nuclear medicine start-up International Isotopes has won a major contract that will help the company in its quest to become a supplier of medical radioisotopes (SCAN 9/3/97). The company has signed a deal to provide its radioactive seeds to Imagyn
Nuclear medicine start-up International Isotopes has won a major contract that will help the company in its quest to become a supplier of medical radioisotopes (SCAN 9/3/97). The company has signed a deal to provide its radioactive seeds to Imagyn Medical Technologies, which will have exclusive worldwide rights to market the seeds for brachytherapy prostate cancer treatment, according to Newport Beach, CA-based Imagyn.
International Isotopes, of Denton, TX, will develop and manufacture the radioactive seeds for distribution through Imagyn's direct sales force. Imagyn will pay International Isotopes $1 million to develop the seeds and has agreed to purchase seeds for three years. Imagyn anticipates that it will file a 510(k) application for the company's initial brachytherapy product, iodine-125, with the Food and Drug Administration by March 31.
In other Imagyn news, the company has announced that it will close its Laguna Niguel, CA, plant and move its endoscope manufacturing facility to Costa Mesa, CA. As part of its consolidation, the firm is reducing its work force by about 120 people.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
